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Repeated Intracoronary Beta Radiation for Recurrent
In-Stent Restenosis
Edoardo De Benedetti,* Donald Latchem, Christian Roguelov, Philippe Coucke,
Charles Seydoux, Jean-Jacques Goy, Philip Urban,† and Eric Eeckhout
More than 70% of percutaneous coronary interventions are followed by a stent implan-
tation. In-stent restenosis still occurs in 20-30% of patients and remains a therapeutic
challenge. At present only vascular brachytherapy has been shown to be an effective
treatment option. We report here one case of recurrent in-stent restenosis after vascular
brachytherapy that was successfully treated by a second beta radiation treatment.
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INTRODUCTION
Intracoronory stents improve clinical and angiographic
outcomes when compared with balloon angioplasty, as
shown in BENESTENT and STRESS trials [1,2]. Today,
in most hospitals, more than 70% of percutaneous coro-
nary interventions are followed by a stent implantation.
However, in-stent restenosis still occurs in 20%–30%
of patients and remains a therapeutic challenge [1,2]. At
present, only vascular brachytherapy (VBT) has been
shown to be an effective treatment option [3]. Neverthe-
less, this therapy is not 100% effective and recurrent
in-stent restenosis after brachytherapy occurs. We report
here one case of recurrent in-stent restenosis after VBT
that was successfully treated by a second beta radiation
treatment.
CASE REPORT
A 67-year-old white female was first admitted to our
hospital in 1997 for angina associated with dyspnea and
dizziness. Her past medical history was negative except
for hyperlipidemia and tobacco consumption. Physical
examination was unremarkable. In view of her symp-
toms, she subsequently underwent cardiac catheterization
without a prior stress test. Selective coronary angiogra-
phy revealed two-vessel disease with a tight stenosis of
both the circumflex (LCx) and the right coronary arteries
(RCA). The left ventriculogram showed a normal ejec-
tion fraction. A double angioplasty with stent implanta-
tion of the LCx (NIR 3.5/9 mm, Boston Scientific,
Natick, MA) and of the RCA (Angiostent 3.5/35 mm,
Angiodynamics, Queensbury, NY) was carried out. The
stent implanted in the RCA was deployed at 8 atm. The
hospital course was uneventful, but 4 months later chest
pain recurred and a stress test was positive. A repeat
angiogram showed a widely patent CX stent but a dif-
fuse, proliferative in-stent restenosis on the RCA that
was successfully treated by conventional balloon angio-
plasty only (4.0/20 mm balloon). The patient did well but
after 3 months chest pain recurred and a new stress test
was positive. The angiogram showed a new diffuse re-
stenosis in the distal part of the stent of the RCA. This
was again treated by balloon angioplasty with a good
angiographic immediate result. Four months later, angina
symptoms recurred and were complicated this time by
congestive heart failure. The angiogram showed an in-
stent restenosis in the distal part of the stent (Fig. 1A). A
new balloon PTCA was performed, followed by VBT
using a 30 mm long 90Sr/Y beta-emitting source (Beta-
Cath, Novoste) delivering 20 Gy to 2 mm from the
source with an excellent final result (Fig. 1B). However,
3 months later, a new angiogram, performed because of
the abrupt onset of unstable angina 2 weeks after the
ticlopidine was stopped, showed a late thrombotic occlu-
sion that could be successfully treated by further balloon
angioplasty and the reintroduction of long-term treatment
with clopidogrel. Symptoms recurred 8 months later and
a new diffuse in-stent restenosis (Fig. 1C) was treated
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with a cutting balloon 4.0 mm in diameter and 10 mm
long followed by a second VBT using a 30 mm long
90Sr/Y source (Novoste) delivering 22 Gy at 2 mm from
the source (Fig. 1D). Seven months later, the patient was
free of symptoms and a final angiogram showed an
excellent result (Fig. 1E).
DISCUSSION
Proliferative in-stent restenosis remains a therapeutic
challenge for the interventional community. Several pat-
terns of in-stent restenosis have been described, the oc-
clusive form being the most difficult to treat [4]. Balloon
Fig. 1. A: Coronary angiogram showing a significant in-stent restenosis in the right coronary
artery. B: Final result after balloon angioplasty followed by beta radiation. C: A new in-stent
restenosis is present after the first brachytherapy treatment. D: Position of the 30 mm source
train (between the radiopaque markers) within the delivery catheter, with adequate overlap of
the restenotic segment. E: No significant restenosis at the 7-month follow-up angiogram.
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angioplasty [5], balloon angioplasty followed by a new
stent [6], rotablation [7], cutting balloon angioplasty [8],
and other techniques are often unsuccessful, especially in
diffuse forms of restenosis. Only VBT has been shown to
be highly effective to treat this iatrogenic entity either
with a gamma [3,9,10] or a beta source [11,12]. In these
different studies, restenosis rate (taking into account the
entire segment, not only the initial lesion) decreased from
50%–55% in the placebo (PTCA) to 15%–20% in the
irradiated arm.
Since 1998, we have been performing VBT in our
institution as the treatment of choice for in-stent reste-
nosis. We describe here a patient with a very symptom-
atic and aggressive form of in-stent restenosis that re-
curred despite several attempts with balloon angioplasty.
Surgery was not considered because of the patient’s
preference and because of single RCA involvement.
A first treatment with beta radiation was given but a
new restenosis occurred. After reviewing the angiogram,
it was clear that the 30 mm long beta source had entirely
covered the whole segment that was injured by the bal-
loon and that geographical miss has not occurred. We
then postulated that an insufficient dose of radiation was
delivered to the vessel wall and therefore irradiated the
vessel a second time. The procedure was preceded by
balloon angioplasty with a cutting balloon. A second
dose of 22 Gy at 2 mm from the source, calculated from
the quantitative angiographic measurements, was deliv-
ered and the immediate result was excellent. The patient
was free of angina and an elective 7-month follow-up
angiogram showed the absence of restenosis. Moreover,
there was no coronary aneurysm, a side effect described
when using high dose of radiation [13].
Several trials have shown that gamma brachytherapy
is very effective for the treatment of in-stent restenosis.
Gamma radiation has a superior depth-dose gradient
compared with beta source. It is therefore possible that a
noncentered beta source applied in a big vessel (3.5 mm
in our patient) delivers a suboptimal dose of radiation to
the deep vessel wall (media and adventitia), which could
explain occasional failure of this treatment. However, the
BETA WRIST trial [14] suggests that beta radiation is
also effective for in-stent restenosis, which has been
confirmed by the recent results of the START and
INHIBIT trials [11,15].
The optimal dose of radiation to prevent restenosis is
still unknown. The recent study by Verin et al. [16]
utilizing beta radiation for de novo lesions suggests that
18 Gy at a tissue depth of 1 mm not only prevents the
renarrowing of the lumen but actually induces luminal
enlargement (positive remodeling). The present case sug-
gests that an insufficient dose may be one of the cause of
VBT failure. It is well known that the angiogram often
underestimate the true vessel size. We therefore have
changed our policy from 1999 on and calculate the do-
simetry to deliver from the intravascular ultrasound mea-
surements. Since the targets of radiotherapy are the
smooth muscle cells localized in the media and the ad-
ventitia, intravascular ultrasound measurements may al-
low an optimal dosimetry. This may explain occasional
treatment failure when the dosimetry is based on quan-
titative angiographic measurements alone.
To our knowledge, this is the first report of a repeated
VBT treatment for in-stent restenosis with a cumulative
dose of 42 Gy (prescribed at 2 mm of depth) adminis-
tered over 7 months. Even though it is difficult to com-
pare the dose delivered by different systems and isotopes,
in the first human study conducted by Condado et al.
[13], a dose between 19 and 55 Gy was prescribed in de
novo or restenotic lesions. Two subacute thrombosis
(9%) and four pseudoaneurysms (18%) were reported
during the early follow-up but extended follow-up to 5
years has not been associated with any further unex-
pected side effects (J.A. Condado, personal communica-
tion).
Subacute thrombosis after radiotherapy can be the
consequence of a delayed reendothelialisation and has
been linked to a new stent implantation [10]. However,
clinical data have so far not shown any relationship
between the dose administred and the subsequent oc-
curence of late thrombosis [16]. It is possible that high
doses of radiotherapy can increase the incidence of cor-
onary pseudoaneurysm [13] and/or late stent malapposi-
tion.
Figure 1 (Continued.)
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Longer-term clinical and angiographic follow-up in
this case are obviously needed. Large-scale dose-finding
studies with longer follow-up (5 years) seem imperative
since the recent approval by the FDA of two devices for
the delivery of radiation opens the route to the diffusion
of this new technique in many catheterization laborato-
ries throughout the world.
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